Section edited by: Marek Malecki
The primary objective of this section is to promote significant advances in vaccination and immunotherapy research. Of special focus are research endeavors that are entering, or have entered, “first-in-human” or phase 1 clinical trials, and areas of specific interest include: Prophylactic vaccines for HIV, HBV, HPV, HCV, Zika, Dengue, Yellow fever, Influenza, MRSA, VRSA or cancer; therapeutic vaccines for cancer; synthetic, recombinant, DNA vaccines; therapies for viral diseases; immunosuppressants; immunomodulators; therapeutics for autoimmune diseases; adverse effects and iatrogenic outcomes of vaccines and immunotherapeutics; phage, yeast, mammalian, human display based in vitro evolution; GMP production of vaccines; GMP production of antibodies and recombinant proteins; oncolytic viruses; antibody guided virotherapeutics; and viral vectors of immunotherapeutics.